MedDataX Logo

To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.

NCT ID: NCT00141414

Last Updated: 2007-01-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

82 participants

Study Classification

INTERVENTIONAL

Study Start Date

1997-11-30

Study Completion Date

2005-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the long-term safety of pregabalin in refractory partial epilepsy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

NCT00141245

Seizure Disorder, Partial
COMPLETED PHASE3

Pregabalin Open-Label Extension Trial in Patients With Partial Seizures

NCT00143143

Epilepsies, Partial Epilepsy, Complex Partial
COMPLETED PHASE3

To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures

NCT00141388

Seizure Disorder, Partial
COMPLETED PHASE3

To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

NCT00141336

Seizure Disorder, Partial
COMPLETED PHASE3

Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

NCT00150293

Seizure Disorder, Partial
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy, Partial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pregabalin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have received double-blind study medication and wish to receive open-label pregabalin.

Exclusion Criteria

* Pregnant or considering becoming pregnant.
* Receiving any concomitant medication that could alter the effectiveness of their medication response or seizure frequency.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Little Rock, Arkansas, United States

Site Status

Pfizer Investigational Site

Los Angeles, California, United States

Site Status

Pfizer Investigational Site

Stanford, California, United States

Site Status

Pfizer Investigational Site

Miami, Florida, United States

Site Status

Pfizer Investigational Site

Plantation, Florida, United States

Site Status

Pfizer Investigational Site

Indianapolis, Indiana, United States

Site Status

Pfizer Investigational Site

Indianapolis, Indiana, United States

Site Status

Pfizer Investigational Site

Baltimore, Maryland, United States

Site Status

Pfizer Investigational Site

Baltimore, Maryland, United States

Site Status

Pfizer Investigational Site

Boston, Massachusetts, United States

Site Status

Pfizer Investigational Site

Ann Arbor, Michigan, United States

Site Status

Pfizer Investigational Site

Saint Paul, Minnesota, United States

Site Status

Pfizer Investigational Site

Chesterfield, Missouri, United States

Site Status

Pfizer Investigational Site

New York, New York, United States

Site Status

Pfizer Investigational Site

New York, New York, United States

Site Status

Pfizer Investigational Site

Rochester, New York, United States

Site Status

Pfizer Investigational Site

The Bronx, New York, United States

Site Status

Pfizer Investigational Site

Winston-Salem, North Carolina, United States

Site Status

Pfizer Investigational Site

Cleveland, Ohio, United States

Site Status

Pfizer Investigational Site

Columbus, Ohio, United States

Site Status

Pfizer Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Nashville, Tennessee, United States

Site Status

Pfizer Investigational Site

Madison, Wisconsin, United States

Site Status

Pfizer Investigational Site

Madison, Wisconsin, United States

Site Status

Pfizer Investigational Site

Bonn, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1008-008

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pregabalin In Partial Seizures: An Open-Label, International, Multicenter Add-On Therapy Trial.
NCT00141427 COMPLETED PHASE4
Once-A-Day Pregabalin For Partial Seizures
NCT01262677 COMPLETED PHASE3
Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures
NCT00596466 COMPLETED PHASE3
Pregabalin Epilepsy Add-On Trial
NCT00141258 COMPLETED PHASE3
Pregabalin In Partial Seizures Extension Study
NCT00143130 COMPLETED PHASE3
Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures
NCT00448916 COMPLETED PHASE3
Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy
NCT00280059 COMPLETED PHASE3
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
NCT00351611 COMPLETED PHASE4
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
NCT00437281 COMPLETED PHASE1/PHASE2
Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures
NCT00524030 TERMINATED PHASE3
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
NCT01463306 COMPLETED PHASE3
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
NCT02072824 COMPLETED PHASE3
A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.
NCT01747915 COMPLETED PHASE3
Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial
NCT00407797 TERMINATED PHASE4
Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy
NCT00235755 COMPLETED PHASE3
Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures
NCT01147003 COMPLETED PHASE2
An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures
NCT00372528 TERMINATED PHASE3
Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures
NCT01167335 WITHDRAWN PHASE2
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
NCT00866775 COMPLETED PHASE3
A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years
NCT01389596 COMPLETED PHASE3
Study of Predictors of Response to Anti Epilepsy in Epilepsy
NCT02883712 TERMINATED
Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery
NCT00887861 COMPLETED PHASE2
Clinical Study With Lyrica In Patients Suffering From Epilepsy
NCT00922987 COMPLETED
Non-Interventional Study With LYRICA (Pregabalin) In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency
NCT00684424 COMPLETED
Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy
NCT00232596 COMPLETED PHASE3